Abstract: A lead device is provided for a medical treatment apparatus, where the lead device includes protruding anchoring mechanisms for anchoring the lead device in tissue. The anchoring mechanism include permanent anchoring mechanisms, or a combination of permanent and dissolvable anchoring mechanisms, to anchor the device in tissue. The anchoring mechanism resists migration of the lead device in at least one or both axial directions.

Abstract: Embodiments provide methods and apparatus for manufacturing a microtablet from a precursor material such as a pharmaceutical powder. Various embodiments provide a method which includes compressing the powder to form a compressed mass of a selected density and repeatedly compacting the compressed mass to increase the density of the compressed mass and form a microtablet. Related methods and apparatus are provided.

Abstract: A lead device is provided for a medical treatment apparatus, where the lead device includes mechanisms for anchoring the lead device in tissue.

Abstract: Embodiments of the invention provide apparatus, systems and methods for stimulating tissue in the urinary tract to initiate or facilitate urination. One embodiment provides an external urinary sphincter stimulation (EUSS) catheter for stimulating the external urinary sphincter (EUS), where the EUSS catheter includes nerve stimulation electrodes (NSES) for delivering current to nerves within or around the EUS in order to relax the EUS prior to urination. Other embodiments provide a system for stimulating the EUS including the EUSS catheter and a controller operatively coupled to the EUSS catheter, where the controller includes a pulse generator for delivering current to the NSES. Other embodiments provide methods for positioning the EUSS catheter in the patient's body including in the EUS using a urethral approach. Embodiments of the invention are particularly useful for initiating and/or controlling urination for patients who have lost the ability to voluntarily urinate due to neurogenic bladder dysfunction.

Abstract: Various embodiments of the invention provide methods of treating diabetes and other glucose regulation disorders. In one embodiment, the method comprises removing L-cells from a donor, obtaining stem cells from a patient, and culturing the L-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived L-cells (SCDLC). An amount of the SCDLC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food. In another embodiment, the method comprises removing K-cells from a donor, obtaining stem cells from a patient, and culturing the K-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived K-cells (SCDKC). An amount of the SCDKC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food.

Abstract: Embodiments of the invention provide multi-stage biodegradable drug delivery platforms and methods for the subcutaneous delivery of therapeutic agents (TA). Embodiments of the platform may be configured to subcutaneously deliver a first dose of a first TA which is absorbed into the body and/or blood stream (BBS) to produce a first therapeutic effect for a first selectable time period (STP), and subsequently after a second STP, deliver a second dose of a second TA which is absorbed into the BBS to produce a second therapeutic effect for a third STP. An embodiment of the platform may comprise a body having a tissue-penetrating end, a primary cavity having a first TA dose and a shell having a secondary cavity having a second TA dose. The first TA dose is released after the first STP and the second TA dose is released after the second STP by biodegradation of the shell.

Abstract: Embodiments of the invention provide apparatus and methods for stimulating L cells in the intestinal tract to produce incretins for the treatment of conditions including diabetes and obesity. Many embodiments provide a method and apparatus for the treatment of diabetes by electrically stimulating L-cells to secrete incretins to stimulate or otherwise modulate the production of insulin. Particular embodiments provide a swallowable capsule for stimulating L-cells in the intestinal tract as the capsule moves through the tract. The capsule can include two or more electrodes for providing electrical stimulation to L-cells, a power source for powering one or more components of the capsule, a sensor for sensing the location of the capsule in the intestinal tract; a controller and a waveform generator for generating the electrical signals emitted by the electrodes to stimulate the L-cells to secrete incretins such as GLP-1 to stimulate insulin production for glucose regulation of diabetic conditions.

Abstract: Embodiments of the invention provide apparatus, systems and methods for stimulating tissue in the urinary tract to initiate or facilitate urination. One embodiment provides an external urinary sphincter stimulation (EUSS) catheter for stimulating the external urinary sphincter (EUS), where the EUSS catheter includes nerve stimulation electrodes (NSES) for delivering current to nerves within or around the EUS in order to relax the EUS prior to urination. Other embodiments provide a system for stimulating the EUS including the EUSS catheter and a controller operatively coupled to the EUSS catheter, where the controller includes a pulse generator for delivering current to the NSES. Other embodiments provide methods for positioning the EUSS catheter in the patient's body including in the EUS using a urethral approach. Embodiments of the invention are particularly useful for initiating and/or controlling urination for patients who have lost the ability to voluntarily urinate due to neurogenic bladder dysfunction.

Abstract: A patch pump includes a needle assembly, a reservoir, a preparation, and an inflatable component. The needle assembly includes a cannula, and a plunger slidably disposed in the cannula. The plunger has a pointed tip and is structured to move within the cannula upon application of a force on the plunger such that the pointed tip of the plunger extends from the cannula to form a channel in a tissue of a subject. The reservoir is fluidically coupled to the needle assembly, and the preparation is contained in the reservoir. The inflatable component is structured to, upon inflation, press against the reservoir to force the preparation from the reservoir and into a flowpath between the reservoir and the cannula.

Abstract: A bladder fullness monitoring systems includes a controller and an active optical sensor that is affixed to a patient's bladder. The sensor emits light onto the bladder and further detects light reflected from the bladder, in order to generate an output signal that indicates an amount of emitted light was reflected back to the detector. The controller is coupled to the optical sensor to receive and interpret the output signals, e.g., to determine when the bladder is full. The controller may be operatively coupled to a urinary control apparatus which uses the output signals to trigger urination in patients who have lost the ability to voluntarily urinate. Embodiments are particularly useful for monitoring bladder fullness in patients who have lost bladder sensation and/or the ability to voluntary urinate and rely on a urinary control apparatus in order to urinate.

Abstract: Embodiments provide methods and apparatus for manufacturing a microtablet from a precursor material such as a pharmaceutical powder. Various embodiments provide a method which includes compressing the powder to form a compressed mass of a selected density and repeatedly compacting the compressed mass to increase the density of the compressed mass and form a microtablet. Related methods and apparatus are provided.

Abstract: An illustrative drug delivery system implantable in a recipient may include a connection assembly, a source catheter, and a microcatheter. A proximal end portion of the source catheter may be configured to be fluidically connected to a fluid source configured to provide a fluid (e.g., a neurotherapeutic drug). A distal end portion of the source catheter may be configured to be fluidically connected to the connection assembly. The microcatheter may include a proximal end portion configured to be fluidically connected to the connection assembly and a distal end portion comprising an elution opening configured to elute the fluid to a target location (e.g., a brain) within a recipient. The fluid source may be configured to provide the fluid to the target location by way of the source catheter, the connection assembly, and the microcatheter.

Abstract: Embodiments of the invention provide devices and systems to monitor fullness of a patient’s bladder. One embodiment of a bladder fullness (BF) measure system comprises a sensor device (SD) and a controller. The SD generates an output signal (OS) based on the force exerted by the bladder against SD the wherein the OS corresponds to a degree of BF. The SD may be attached to the bladder wall or adjoining tissue and positioned between the bladder and the pubic bone such that the SD is not affected by tissues force other than that from the bladder. The controller connects to the SD and causes an associated implant to perform a function when the SD output signal exceeds a predetermined threshold. Embodiments are particularly useful for providing information on BF to patients suffering from spinal injury or other conditions whereby they have lost the ability to sense BF and/or voluntarily urinate.

Abstract: Embodiments of the invention provide compositions including bio degradable polymers, medical implants fabricated from these compositions and methods of using such implants. Many embodiments provide medical implants comprising a first polymer backbone having a first rate of biodegradation and a second polymer backbone having a second rate of biodegradation faster than the first rate. In some embodiments, the second backbone is configured to be replaced by a natural tissue layer. The first backbone provides a scaffold for the implant while the second backbone degrades. This scaffold can enhance mechanical properties of the implant including various aspects of mechanical strength such as tensile, bending, hoop and yield strength; and elasticity. The scaffold also serves to maintain a minimum level of structural support of the implant during the period of degradation of the second backbone or for the entire life of the implant so that the implant does not mechanically fail.

Abstract: A header lock assembly includes a header lock pin and mating lead lock collar that provide a releasable coupling for attaching one or more leads to a device. The header lock assembly is configured to engage the lead to assure closure while not applying undue pressure on the lead. One or more notches in the header lock pin allow the lead to pass the header lock pin unimpeded while the header lock assembly is in an unlocked configuration. Rotation of the header lock pin engages a circumferential groove in the lead lock collar to secure the lead to the header. A slot in the top of the header lock pin provides an interface surface with a lead locking tool for rotating the header lock pin. The slot orientation provides a visual indication of the header lock assembly being in a locked or unlocked configuration.

Abstract: Embodiments of the invention provide devices and systems to monitor fullness of a patient's bladder. One embodiment of a bladder fullness (BF) measure system comprises a sensor device (SD) and a controller. The SD generates an output signal (OS) based on the force exerted by the bladder against SD the wherein the OS corresponds to a degree of BF. The SD may be attached to the bladder wall or adjoining tissue and positioned between the bladder and the pubic bone such that the SD is not affected by tissues force other than that from the bladder. The controller connects to the SD and causes an associated implant to perform a function when the SD output signal exceeds a predetermined threshold. Embodiments are particularly useful for providing information on BF to patients suffering from spinal injury or other conditions whereby they have lost the ability to sense BF and/or voluntarily urinate.

Abstract: A cuff is described for a target anatomic feature within a body, along with a system for utilizing the cuff. The cuff includes a band defining a circumferential opening extending along a length of the band; and a pair of engagement surfaces defined by or affixed to the cuff, the engagement surfaces structured for application of a spreading force to be distributed continuously along a portion of the circumferential opening, thereby increasing the circumferential opening and expanding the cuff for a closed configuration to an open configuration sized for placement of the cuff. The cuff is structured to remain in the closed configuration in the absence of the spreading force and automatically return to the closed configuration after removal of the spreading force.

Abstract: An apparatus is provided for remotely powering an implantable medical device (IMD) positioned at a target treatment location within a patient. The apparatus is configured to be positioned at or near an external skin surface of the patient in proximity to the target treatment location. The apparatus includes an induction coil which, when placed in proximity to the IMD, forms an inductive transcutaneous power link with the IMD such that when the induction coil is supplied with a current, the induction coil inductively and transcutaneously delivers power to the IMD. An aerogel layer is disposed between the induction coil and the patient's skin surface. The aerogel layer is configured to receive heat generated from the induction coil and regulate heat dissipation from the aerogel layer to minimize heat transfer to the patient.

Abstract: This application relates to cell delivery articles and methods for delivering cells into the body in a manner that allows them to incorporate into surrounding tissue and express cell products. The cell delivery articles are generally capable of maintaining viability of the cells for a period of time that allows such incorporation to occur. Additionally, a cell delivery article may include a bio-ghost coating that prevents the cell delivery article from being recognized by the immune system, and/or minimizes or prevents development of fibrotic tissue which can interfere with nutrients and oxygen entering the cell delivery article and reaching the cells. A cell delivery article may be formulated for delivery by various routes of administration.

Abstract: A catheter for measuring pressure in the urinary tract of a patient includes a catheter body having a proximal and distal end. A plurality of lumens is formed in the catheter body, and an adaptor is coupled to the proximal end of the catheter body. The adaptor includes a port for each lumen. A first pressure sensor, typically including a balloon, is fluidically coupled to a first lumen and is configured and positioned to measure pressure in a urethra of the patient. A second pressure sensor, also typically including a balloon, is fluidically coupled to a second lumen and is configured and positioned on the catheter body to measure pressure in a bladder of the patient. An expandable retention member, which may be coupled to a third lumen, is positioned on the catheter body between the first and second expandable pressure sensors so that the catheter body may be retained at a selected location in the urinary tract to properly position the fluid pressure sensors in the bladder and urethra, respectively.